PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
G&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-488.33%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-14.77%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-14.77%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
-25.91%
Interest expense reduction while AXSM shows 24.56% growth. Joel Greenblatt would examine advantage.
18928.57%
D&A growth while AXSM reduces D&A. John Neff would investigate differences.
439.10%
EBITDA growth exceeding 1.5x AXSM's 35.57%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
10.94%
Operating income growth below 50% of AXSM's 35.57%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
70.03%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.20%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
11.95%
Net income growth 50-75% of AXSM's 19.26%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
11.92%
EPS growth 50-75% of AXSM's 20.49%. Martin Whitman would scrutinize operations.
11.92%
Diluted EPS growth 50-75% of AXSM's 20.49%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.